Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US
Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind
Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in
CVS Health has said it will remove AbbVie’s big-selling immunology drug Humira from most of its national formulary lists of reimbursable products, and offer biosimilar ver
